Ensysce Biosciences discloses $77.2 million private securities offering
A Form D filing shows the company sold equity tied to a business combination transaction, with 44 investors participating.
SEC filing
Latest
4 stories
Thursday, August 20
Thursday, August 13
Ensysce completes Cy Biopharma acquisition, adds CRPS candidate CY200
The San Diego biotech folded in Cy Biopharma on August 6, 2026, gaining an Orphan Drug-designated pain therapy and up to $77 million in new funding.
SEC filing
Thursday, August 6
Ensysce completes Cy Biopharma acquisition, lines up up to $77 million financing
The deal brings Ensysce a Phase 2-stage CRPS therapy with FDA Orphan Drug Designation, funded through a two-tranche private placement.
SEC filing
Wednesday, July 15
Ensysce Biosciences' chief operating officer resigns effective July 10, 2026
The company disclosed in a filing that Jeffrey Millard stepped down from the COO role, with the resignation taking effect the same day it was submitted.
SEC filing